Anteris Technologies Global Corp AVR
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-12-13 |
| Shares Out. | 97,340,000 |
| Website | anteristech.com/ ↗ |
| Phone | 18009279800 |
| Employees | 174 |
| Revenue | $494,000 |
| Gross Profit | $380,000 |
| Net Income | -$22.9M |
| Free Cash Flow | -$86.8M |
| Total Assets | $294.7M |
| Total Liabilities | $16.3M |
| Equity | $278.4M |
About Anteris Technologies Global Corp
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
Anteris Technologies Global Corp is a publicly traded company under the ticker symbol AVR on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)